v3.25.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Cash Flows from Operating Activities:    
Net loss $ (12,537,472) $ 4,464,079
Adjustments to reconcile net (loss) income to net cash used in operating activities:    
Interest income on investments held in Trust Account (548,676) (5,813,213)
Change in fair value of convertible note 9,105,853
Interest expense - debt discount 891,624 8,966
Increase in current assets    
Prepaid expenses 71,884 599,440
Increase in current liabilities    
Accounts payable and accrued liabilities 878,609 (28,629)
Due from Sponsor (36,503)
Due to affiliate 120,000 116,250
Net cash used in operating activities (2,054,680) (653,107)
Cash Flows from Investing Activities:    
Cash withdrawn from Trust Account in connection with redemptions 13,781,323 284,916,127
Net cash provided by (used in) investing activities 13,781,323 284,916,127
Cash Flows from Financing Activities:    
Proceeds from Subscription Agreement loan 1,711,313
Redemption of ordinary shares (13,781,323) (284,916,127)
Proceeds from Sponsor note 343,367 155,848
Net cash used in by financing activities (11,726,643) (284,760,279)
NET CHANGE IN CASH (497,259)
CASH, BEGINNING OF THE PERIOD 497,259
CASH, END OF THE PERIOD
Non-cash investing and financing activities:    
Deferred underwriting commissions payable charged to additional paid in capital (10,812,500)
Remeasurement of Class A ordinary shares to redemption value 548,676 5,813,213
Sponsor shares contributed for no redemption of shares 784,302 118,298
Conversion of Class B shares to Class A 719
Aspire Biopharma Inc [Member]    
Cash Flows from Operating Activities:    
Net loss (1,309,872) (359,070)
Adjustments to reconcile net (loss) income to net cash used in operating activities:    
Depreciation and amortization
Interest expense - debt discount 97,988
Increase in current assets    
Prepaid expenses (109,356) (12,500)
Subscription Receivable
Increase in current assets (109,356) (12,500)
Increase in current liabilities    
Accounts payable and accrued liabilities 247,846 50,038
Short-term loans from shareholders (net) 906,196 332,668
Increase in current liabilities 1,154,042 382,706
Net cash used in operating activities (265,186) 11,136
Cash Flows from Investing Activities:    
Net cash provided by (used in) investing activities
Cash Flows from Financing Activities:    
Series A Preferred stock, par value $0.0001 32
Additional paid in capital 257,613
Net cash used in by financing activities 257,645
NET CHANGE IN CASH (7,541) 11,136
CASH, BEGINNING OF THE PERIOD 11,174 38
CASH, END OF THE PERIOD 3,633 11,174
Supplemental disclosure of cash flow information:    
Cash paid for interest
Cash paid for income taxes 1,013
Note Payable addition from OID $ 280,549